Prominent publications by Bernard Asselain

KOL Index score: 17070

PURPOSE: The PACS 01 trial compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential regimen of three cycles of FEC followed by three cycles of docetaxel (FEC-D) as adjuvant treatment for women with node-positive early breast cancer.

PATIENTS AND METHODS: Between June 1997 and March 2000, 1,999 patients with operable node-positive breast cancer were randomly assigned to either FEC every 21 days for six cycles, or three cycles of FEC followed by three ...

Also Ranks for: Docetaxel Chemotherapy |  cycles fec |  positive breast |  adjuvant epirubicin |  fnclcc pacs
KOL Index score: 14212

PURPOSE The indications of adjuvant chemotherapy for patients with estrogen receptor (ER) -positive breast cancer are controversial. We analyzed the predictive value of Ki67, HER2, and progesterone receptor (PR) expression for the efficacy of docetaxel in patients with ER-positive, node-positive breast cancer. PATIENTS AND METHODS Expression of Ki67, HER2, and PR was measured by immunohistochemistry in tumor samples from 798 patients with ER-positive breast cancer who participated in ...

Also Ranks for: Ki67 Expression |  positive breast |  docetaxel patients |  estrogen receptor |  predictive biomarkers
KOL Index score: 12109

PURPOSE: To determine the incidence and prognostic significance of eradication of cytologically proven axillary lymph node metastases in breast cancer patients treated with primary chemotherapy. PATIENTS AND METHODS: Between January 1985 and December 1994, 152 breast cancer patients with invasive T1 to T3 tumors and axillary metastases cytologically proven by fine-needle sampling underwent primary chemotherapy followed by lumpectomy or mastectomy, level I and II axillary lymph node ...

Also Ranks for: Primary Chemotherapy |  breast cancer patients |  prognostic significance |  lymph nodes |  cytologically proven
KOL Index score: 11406

As tumours in BRCA1/2 mutation carriers might be more sensitive to radiation, we investigated after long-term follow-up whether mutation status influenced the rate of ipsilateral and contralateral breast cancers after breast-conserving treatment (BCT). BRCA1 and BRCA2 genes were screened for germline mutations in 131 patients with a family history of breast and/or ovarian cancer who had undergone BCT and radiotherapy. Patients were matched to 261 controls with sporadic breast cancer ...

Also Ranks for: Mutation Carriers |  brca1 genes |  age diagnosis |  conserving treatment |  breast neoplasms
KOL Index score: 11216

BACKGROUND: Lung cancer is the commonest cause of death due to cancer in the world. Non-small-cell lung carcinoma (NSCLC) represents about 80% of overall lung cancer cases worldwide. An accurate predictive model of mortality in patients with NSCLC could be useful to clinicians, policy makers, and researchers involved in risk stratification. The objective of this study was to develop and validate a simple prognostic index for 4-year mortality in patients with NSCLC by use of information ...

Also Ranks for: Cell Lung |  patients nsclc |  year mortality |  validation cohort |  carcinoma small
KOL Index score: 11203

BACKGROUND: Using surrogate end points for overall survival, such as disease-free survival, is increasingly common in randomized controlled trials. However, the definitions of several of these time-to-event (TTE) end points are imprecisely which limits interpretation and cross-trial comparisons. The estimation of treatment effects may be directly affected by the definitions of end points. The DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) ...

Also Ranks for: Breast Cancer |  datecan initiative |  event endpoints |  tte points |  randomized controlled trials
KOL Index score: 11192

The aim of this study was to assess a potential advantage in survival by neoadjuvant as compared to adjuvant chemotherapy. 414 premenopausal patients with T2-T3 N0-N1 M0 breast cancer were randomised to receive either four cycles of neoadjuvant chemotherapy (cyclophosphamide, doxorubicin, 5-fluorouracil), followed by local-regional treatment (group I) or four cycles of adjuvant chemotherapy after primary irradiation +/- surgery (group II). Surgery was limited to those patients with a ...

Also Ranks for: Adjuvant Chemotherapy |  premenopausal patients |  breast conserving surgery |  randomised trial |  neoplasm recurrence
KOL Index score: 11045

PURPOSE: Although all studies confirm that BRCA1 tumors are highly proliferative and poorly differentiated, their outcomes remain controversial. We propose to examine, through a cohort study, the pathologic characteristics, overall survival, local recurrence, and metastasis-free intervals of 40 patients with BRCA1 breast cancer.

PATIENTS AND METHODS: A cohort of 183 patients with invasive breast cancer, treated at the Institut Curie and presenting with a familial history of breast and/or ...

Also Ranks for: Brca1 Mutation |  breast cancer |  worse outcome |  tumor characteristics |  genetic counseling
KOL Index score: 11021

PURPOSE: Incurable metastases develop in approximately 50% of patients with uveal melanoma (UM). The purpose of this study was to analyze genomic profiles in a large series of ocular tumors and liver metastases and design a genome-based classifier for metastatic risk assessment.

METHODS: A series of 86 UM tumors and 66 liver metastases were analyzed by using a BAC CGH (comparative genomic hybridization) microarray. A clustering was performed, and correlation with the metastatic status ...

Also Ranks for: Liver Metastases |  primary tumors |  uveal melanoma |  array cgh |  genomic profiling
KOL Index score: 10885

Neoadjuvant chemotherapy is able to reduce the size of the majority of breast tumours and down-stage axillary-node status. The aim of this study was to assess the prognostic value of persistent node involvement after neoadjuvant chemotherapy. A total of 488 patients with T2-T3, N0-N1 breast cancer treated by neoadjuvant chemotherapy followed by tumour excision and axillary lymph-node dissection between 1981 and 1992 were selected from the Institut Curie database. Median follow-up was 7 ...

Also Ranks for: Neoadjuvant Chemotherapy |  node involvement |  operable breast cancer |  lymphatic metastasis |  neoplasms carcinoma
KOL Index score: 10843

BACKGROUND: Sarcomas are a rare complication of radiotherapy for breast carcinoma and patients have a poor prognosis. The incidence, histology, and management of patients with sarcomas were reviewed in the current study.

METHODS: The authors reviewed the records of 16,705 patients with breast carcinoma. Of these, 13,472 (81%) were treated with megavoltage radiotherapy and 3233 were treated without at the Institute Curie (Paris, France) between 1981 and 1997. Median doses of 50-55 grays ...

Also Ranks for: Breast Carcinoma |  radiation‐induced sarcomas |  radiationinduced neoplasms |  patients radiotherapy |  5 years
KOL Index score: 10518

PURPOSE: Axillary dissection is the standard management of the axilla in invasive breast carcinoma. This surgery is responsible for functional sequelae and some options are considered, including axillary radiotherapy. In 1992, we published the initial results of a prospective randomized trial comparing lumpectomy plus axillary radiotherapy versus lumpectomy plus axillary dissection. We present an update of this study with a median follow-up of 180 months (range, 12 to 221 ...

Also Ranks for: Axillary Dissection |  5 years |  operable breast cancer |  metastasis neoplasm |  breast carcinoma
KOL Index score: 10119

OBJECTIVE: Prospective evaluation of tumor regression during external irradiation for head and neck squamous cell carcinomas and its association with long-term local control.

METHODS AND MATERIALS: Two hundred twenty-eight patients with histologically confirmed squamous cell carcinoma [oral cavity: 59 (26%), oropharynx: 65 (29%), hypopharynx: 37 (16%), larynx: 67 (29%)] were included between January 1986 and December 1990. Curative intent external irradiation delivered 65-70 Gy over a ...

Also Ranks for: Tumor Regression |  local control |  2 weeks |  neck neoplasms humans |  external irradiation

Key People For Breast Cancer

Top KOLs in the world
Ahmedin * *****
united states breast cancer addis ababa
Gabriel * **********
breast cancer neoadjuvant chemotherapy estrogen receptors
Rebecca * ******
united states colorectal cancer incidence rates
Charles * *****
breast cancer gene expression intrinsic subtypes
Freddie *** ****
cancer incidence nordic countries mortality rates
Jacques ******
cancer incidence global burden latin america

Bernard Asselain:Expert Impact

Concepts for whichBernard Asselainhas direct influence:Breast cancer,  Uveal melanoma,  Neoadjuvant chemotherapy,  Institut curie,  Adjuvant chemotherapy,  Lung cancer,  Breast carcinoma,  Primary chemotherapy.

Bernard Asselain:KOL impact

Concepts related to the work of other authors for whichfor which Bernard Asselain has influence:Breast cancer,  Neoadjuvant chemotherapy,  Uveal melanoma,  Lymph node,  Radiation therapy,  Estrogen receptors,  Local control.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Department of Biostatistics, Institut Curie, Paris, France | Biostatistics, ARCAGY-GINECO, Paris, France; | ARCAGY-GINECO, Paris, France; | Méthodologiste, Groupe GINECO, Paris, France | GINECO Group, Paris, France